Treatment advances in lung cancer are moving in two different directions: targeted therapy and immunotherapy. Targeted therapies are designed to interrupt the function of certain molecules driving the growth of cancer cells, stopping the cells from dividing and spreading. Immunotherapy taps the immune system’s illness-fighting tendencies, directing it to locate and kill cancer cells. The FDA has approved a number of targeted therapies and immunotherapies for the treatment of lung cancer.